Welcome to Beacon Equity Research. Today is Friday, 21 December 2007  
 Home     Covered Companies     News and Commentary     Our Team     Ratings     Contact Us     Charity     Affiliates    
 





Newly-acquired Patent for Immunomedics’ (IMMU) Anti-Cancer Product Pushes Shares Higher

The most dreadful thing that a person could ever imagine is to be inflicted with cancer.  Sometimes people equate cancer with death since chances of survival are not high.  Cancer is a group of diseases in which the cells are aggressive, invasive and easily spread to other locations.  Mostly, cancers are caused by abnormalities in the genetic material of the transformed cell.  Some of these abnormalities are caused by harsh elements in the environment which include: radiation, tobacco smoke, chemicals or other infectious elements.  Whatever may be the cause, modern medicine is aiming towards tempering and finding solutions to cure its effects and/or causes.

Immmunomedics, Inc., as a biopharmaceutical company, has a company goal of developing drugs that fight off cancer and other dreaded diseases.  The company has recently announced that it was awarded a patent for its product candidate hPAM4 to treat pancreatic cancer.  The product is characterized as a monoclonal antibody.  Monoclonal antibodies are the most widely used form of cancer immunotherapy.  According to the American Cancer Society, it is a treatment that uses certain parts of the immune system to fight cancer. High demand for the product drove Immunomedics to increase its stock sharply higher, while share prices also went higher.  In recent trading, Immunomedics to the $3.20 range on heavy volume.

About Immunomedics, Inc.  (NASD: IMMU)

Immunomedics, Inc. was founded in 1982 and has its headquarters in Morris Plains, New Jersey.  It is a biopharmaceutical company which develops monoclonal antibody-based products for the treatment of autoimmune, cancer, and other serious diseases.  Its lead product candidate is epratuzumab, which is in two pivotal Phase III trials for the treatment of patients with moderate and severe lupus.  The company’s other products include IMMU-106, which is in Phase I/II clinical trials in patients with B-cell non-Hodgkin’s lymphoma; and PAM4, a humanized monoclonal antibody for the treatment of pancreatic cancer.

For more information on the company, you may visit this website:  http://www.immunomedics.com.
 
< Prev   Next >

 
Copyright 2007 Beacon Equity Research